Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Artiva Biotherapeutics, Inc.’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
9
1 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
Artiva Biotherapeutics, Inc. its own name
named as the applicant on its applications, in US
9 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Mar 6, 2025 | 2025/0073264 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME | Biotechnology | Artiva Biotherapeutics, Inc. |
| Dec 26, 2024 | 2024/0424099 | TREATMENT OF CANCER WITH NK CELLS AND MULTISPECIFIC ENGAGERS | Pharmaceuticals | Artiva Biotherapeutics, Inc. |
| Nov 7, 2024 | 2024/0366664 | TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY | Medical technology | Artiva Biotherapeutics, Inc. |
| Nov 7, 2024 | 2024/0366663 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME | Medical technology | Artiva Biotherapeutics, Inc. |
| Jun 20, 2024 | 2024/0197778 | TREATMENT OF CANCER WITH NK CELLS AND A HER2 TARGETED ANTIBODY | Pharmaceuticals | Artiva Biotherapeutics, Inc. |
| Jun 6, 2024 | 2024/0180962 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | Pharmaceuticals | Artiva Biotherapeutics, Inc. |
| Apr 11, 2024 | 2024/0115704 | TREATMENT OF CANCER WITH NK CELLS AND A CD38-TARGETED ANTIBODY | Medical technology | Artiva Biotherapeutics, Inc. |
| Feb 22, 2024 | 2024/0060046 | EXPANDED AND STIMULATED NATURAL KILLER CELLS | Medical technology | Artiva Biotherapeutics, Inc. |
| Jan 4, 2024 | 2024/0000840 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | Medical technology | Artiva Biotherapeutics, Inc. |
What it applied for, 2024 to 2025: Medical technology 5 · Pharmaceuticals 3 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.